移植后巨细胞病毒感染的诊疗进展

Advances on cytomegalovirus infection after hematopoietic stem cell transplantation and solid-organ transplantation

巨细胞病毒(CMV)是造血干细胞移植和实体器官移植后最常见的感染病原之一,严重影响移植受者的生存质量及生命。控制移植后CMV感染在于早期预防及抢先治疗,并且采用有效的抗病毒治疗方案,改善移植后CMV感染患者的预后。本文就移植后CMV感染的危险因素、诊断、标准治疗方案及新兴治疗方法等方面进行述评,以期提高对该病的认识、了解最新的研究进展。

Cytomegalovirus (CMV) infection continues to be one of the most common infections after hematopoietic stem cell transplantation and solid-organ transplantation(SOT), resulting in significant adverse outcomes and mortality.Management of CMV infection after hematopoietic stem cell transplantation and solid-organ transplantation is based on early prevention and early treatment, using of effective antiviral treatment regimens , thus it has significantly improved the prognosis of CMV infection in transplant recipients.This article reviewed the risk factors, diagnosis, standard treatment and emerging treatment of cytomegalovirus infection after transplantation, in order to improve the understanding of the disease and understand the novel treatment.